BCM
CRBU icon

Bronte Capital Management’s Caribou Biosciences CRBU Stock Holding History

Bronte Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.7K Hold
15,627
– – ﹤0.01% 47
2025
Q4 		$24.8K Buy
+15,627
New +$32.8K ﹤0.01% 39

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bronte Capital Management's CRBU Position: Q1 2026 in Review

Bronte Capital Management held its Caribou Biosciences (CRBU) position steady in Q1 2026 at 15,627 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #47.

Bronte Capital Management first reported a position in CRBU in Q4 2025 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Bronte Capital Management held 15,627 shares of Caribou Biosciences worth $29.7K as of Q1 2026.
  • Bronte Capital Management left its Caribou Biosciences share count unchanged in Q1 2026.
  • Caribou Biosciences made up ﹤0.01% of Bronte Capital Management's portfolio in Q1 2026, its #47 holding.
  • Bronte Capital Management first reported a position in Caribou Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.